# Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

> **NCT05979298** · PHASE2 · UNKNOWN · sponsor: **CureLab Oncology** · enrollment: 40 (actual)

## Conditions studied

- Ovarian Cancer
- Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Gemcitabine
- **BIOLOGICAL:** ELENAGEN

## Key facts

- **NCT ID:** NCT05979298
- **Lead sponsor:** CureLab Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-15
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979298, "Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05979298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*